Optimal treatment strategy for metastatic melanoma patients harboring BRAF-V600 mutations
Optimal treatment strategy for metastatic melanoma patients harboring BRAF-V600 mutations
About this item
Full title
Author / Creator
Publisher
London, England: SAGE Publications
Journal title
Language
English
Formats
Publication information
Publisher
London, England: SAGE Publications
Subjects
More information
Scope and Contents
Contents
BRAF-V600 mutations occur in approximately 50% of patients with metastatic melanoma. Immune-checkpoint inhibitors and targeted therapies are both active as first-line treatments in these patients regardless of their mechanisms of action and toxicities. However, an upfront therapeutic strategy is still controversial. In fact, waiting for results of...
Alternative Titles
Full title
Optimal treatment strategy for metastatic melanoma patients harboring BRAF-V600 mutations
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7307282
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7307282
Other Identifiers
ISSN
1758-8359,1758-8340
E-ISSN
1758-8359
DOI
10.1177/1758835920925219
